Unveiling the Role of mTORC1 in Birt-Hogg-Dubé Syndrome Lung Disease

Birt-Hogg-Dubé (BHD) syndrome stems from mutations in the folliculin (FLCN) gene. While clinicians recognize it for skin lesions and renal tumors, nearly 90% of patients develop Birt-Hogg-Dubé syndrome pulmonary cysts. Recent research explains the elusive mechanisms behind these cystic changes, identifying mTORC1 hyperactivation as a central driver.

Mesenchymal Origin of Birt-Hogg-Dubé Syndrome Pulmonary Cysts

A groundbreaking study utilized lung-specific knockout mouse models to pinpoint the cellular origin of BHD lung pathology. Researchers discovered that deleting the Flcn gene in lung mesenchymal cells—rather than epithelial cells—resulted in significant alveolar enlargement and cyst formation. Consequently, these findings closely mirror the pulmonary disease seen in human BHD patients, suggesting that the stroma plays a critical role in the disease process.

Furthermore, the study demonstrated that FLCN deficiency leads to the overactivity of the mechanistic target of rapamycin complex 1 (mTORC1). This signaling pathway regulates cell growth and metabolism. In both human lung samples and mouse models, researchers observed high levels of mTORC1 activity consistently. Interestingly, inhibiting mTORC1—either genetically or pharmacologically using rapamycin—substantially rescued the pulmonary pathology in mice.

Clinical Implications for BHD Management

Clinicians managing BHD syndrome should recognize that pulmonary manifestations represent a complex interplay involving mesenchymal signaling. This discovery opens the door for potential targeted therapies in the future. Currently, management in India focuses on the surveillance of renal tumors and the prevention of recurrent pneumothorax through pleurodesis. However, the success of rapamycin in experimental models suggests a potential future role for mTOR inhibitors in preventing cyst progression.

Additionally, practitioners should maintain a high index of suspicion for BHD in patients presenting with multiple, thin-walled basal lung cysts. This applies even in the absence of obvious skin or renal findings. Genetic counseling and family screening remain the cornerstones of care for this autosomal dominant condition.

FAQs on BHD Syndrome and Pulmonary Cysts

How do Birt-Hogg-Dubé syndrome pulmonary cysts typically appear on imaging?

They usually appear as multiple, thin-walled, irregularly shaped cysts on HRCT. These lesions typically show a predilection for the lower lobes and subpleural regions of the lungs.

What is the primary clinical risk associated with these pulmonary cysts?

The most significant clinical risk is spontaneous pneumothorax. It occurs in approximately 25% to 40% of BHD patients and often requires pleurodesis to prevent recurrence.

Is there a specific medical treatment to stop cyst formation in BHD?

Currently, there is no approved medical therapy to prevent or reverse cyst formation in humans. However, research into mTORC1 inhibitors shows promise as a potential future therapeutic strategy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Cao K et al. Hyperactivation of mTORC1 signaling mediates folliculin deficiency-induced pulmonary cyst formation in Birt-Hogg-Dubé syndrome. J Clin Invest. 2026 Feb 16. doi: undefined. PMID: 41697734.


2. Nishii T et al. Unique mutation, accelerated mTOR signaling and angiogenesis in the pulmonary cysts of Birt-Hogg-Dubé syndrome. Pathol Int. 2013;63(1):45-51.


3. Gupta N et al. Pulmonary manifestations of Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med. 2017;195(1):11-13.